Kadmon Holdings Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Kadmon Holdings

Access the complete profile.

Kadmon Holdings Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	N/AExact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing 5417 Scientific Research & Development Services
Address	450 East 29th Street New York, NY 10016

Note: Revenues for privately held companies are statistical evaluations.


Kadmon Holdings's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Kadmon Holdings's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • Kadmon Holdings is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Kadmon Holdings Annual Revenue and Growth Rate

Kadmon Holdings	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$10 - $100 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Kadmon Holdings's revenues are gauged from an analysis of company filings.

Kadmon Holdings's Income Statement (based on Industry Averages)

Kadmon Holdings P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Kadmon Holdings is developing and marketing. Kadmon Holdings doesn't have any recent trademark applications, indicating Kadmon Holdings is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
MEIRAGTX Pharmaceutical products to be used in gene therapy	07/30/2015
RIBAONE Pharmaceutical preparations; Pharmaceutical preparations for the treatment of hepatitis C	07/31/2013
RIBADAY Pharmaceutical preparations for the treatment of hepatitis C infection	04/23/2013

See all trademarks and details in the Full Report.

Market Share of Kadmon Holdings's Largest Competitors

A competitive analysis shows these companies are in the same general field as Kadmon Holdings, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Kadmon Holdings. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
PFIZER	New York, NY	100
SUMITOVANT BIOPHARMA	New York, NY	3
ROIVANT SCIENCES	New York, NY	2
TERRASCEND USA	New York, NY	1
KADMON HOLDINGS	New York, NY	0
CALLIDITAS NA ENTERPRISES	New York, NY	0

Other Companies at 450 East 29th Street, New York NY

Company	Headquarters	Revenue ($ MM)
MEIRAGTX	New York, NY	100
MISPRO BIOTECH SERVICES	New York, NY	10
RIVERPARK OPERATING	New York, NY	0

Future Competition: Kadmon Holdings's Fastest Growing Competitors

These companies are in the same general field as Kadmon Holdings and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)